Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma's stock price has fluctuated over the past six months. As of March 27, 2026, the stock price was $7.480, down 4.23% from its previous closing price. In March 2026, the stock price ranged between a high of $9.880 and a low of $7.410, and was down 15.58% for the month. Over the last year, the stock has traded between a low of $5.55 and a high of $11.52. The share price on March 20, 2026, was $8.23, representing a decline of 16.11% from March 24, 2025, when it was $9.81 per share. Key events impacting the stock include a November 2025 announcement of a virtual Key Opinion Leader Meeting to discuss the NXP900 Phase 1b program, a December 2025 announcement of the initiation of the Phase 1b study of NXP900 in combination with osimertinib in patients with NSCLC, and the reporting of 2025 financial results and business progress in February 2026.

Nuvectis Pharma, Inc. exhibits seasonal tendencies based on five years of historical data. February has historically been the strongest month for the stock, with an average return of 32.18% and a win rate of 80%. July tends to be the weakest month, averaging a -10.60% return. The company's seasonal pattern has a consistency score of 68.5, which is considered "Good."

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for oncology. Their pipeline includes NXP800, an oral small molecule GCN2 activator in Phase 1b trials for ovarian carcinoma and cholangiocarcinoma, and NXP900, an oral small molecule inhibitor of the SRC Family of Kinases (SFK), which has completed a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers. The Phase 1b program for NXP900 has been initiated to evaluate its safety and efficacy as a single agent and in combination with other anti-cancer agents, including with osimertinib in patients with non-small cell lung cancer (NSCLC).

Nuvectis Pharma, Inc. is headquartered in Fort Lee, New Jersey, United States.

Nuvectis Pharma's brand reputation is generally positive among analysts, with a focus on its potential in precision oncology. The company has a consensus "Strong Buy" rating due to its rapid clinical development and expansion plans. NXP900 has shown encouraging safety signals in clinical trials. An article in January 2025 highlighted Nuvectis Pharma as a significant investment opportunity. Potential risks include the early stages of its drug development pipeline, funding challenges, and uncertainties in development and commercialization timelines.

Nuvectis Pharma, Inc. has a mixed ownership structure. Approximately 16.00% of the stock is held by institutional shareholders, 42.17% by Nuvectis Pharma insiders, and 41.83% by retail investors. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., and Iridian Asset Management Llc/ct. Ron Bentsur, the CEO, is the largest individual shareholder, owning 3.68 million shares, representing 13.88% of the company. Other significant individual insider owners include Marlio Charles Mosseri and Enrique Poradosu.